title: Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis.
abstract: This retrospective study describes the outcome of patients with chronic myeloid leukaemia after allografting using dose-reduced conditioning with fludarabine and busulphan. Forty-four Philadelphia chromosome (Ph)-positive patients were transplanted in nine German centres; 26 patients were in chronic phase, 11 in accelerated phase and seven in blast crisis. Thirty-four patients achieved complete remission, with 18 alive and disease-free at a median follow-up of 562 d (range 244-922 d). Grade II-IV acute graft-versus-host disease (GVHD) incidence was 43%. Twenty patients died, 15 of causes unrelated to relapse. Risk factors predisposing to graft failure by univariate analysis were an unrelated donor (8/23 compared with a related donor 2/21, P = 0.07) and interferon therapy within 90 d of transplant (4/6 versus 3/17, P = 0.025). At the last follow-up, of 31 patients for whom molecular or cytogenetic data were available, 16 (52%) were polymerase chain reaction-negative, and seven (23%) were Ph-negative by fluorescent in situ hybridization. These findings demonstrate that dose-reduced conditioning with fludarabine and busulphan provides durable engraftment and a low rate of relapse. However, in this population, many of whom were not eligible for high-dose conditioning due to age, reduced performance status, previous complications or extensive pre-treatment, these data highlight the need for effective anti-infectious and GVHD prophylaxis. In addition, this study supports the discontinuation of interferon therapy at least 90 d before transplant
authors.affiliation: Medizinische Klinik und Poliklinik, University Hospital Carl Gustav, Desden, Germany. bornhaeuser@oncocentre.de
authors.forename: M
authors.initials: M
authors.lastname: Bornhäuser
authors.forename: M
authors.initials: M
authors.lastname: Kiehl
authors.forename: W
authors.initials: W
authors.lastname: Siegert
authors.forename: J
authors.initials: J
authors.lastname: Schetelig
authors.forename: B
authors.initials: B
authors.lastname: Hertenstein
authors.forename: H
authors.initials: H
authors.lastname: Martin
authors.forename: R
authors.initials: R
authors.lastname: Schwerdtfeger
authors.forename: H G
authors.initials: HG
authors.lastname: Sayer
authors.forename: V
authors.initials: V
authors.lastname: Runde
authors.forename: N
authors.initials: N
authors.lastname: Kröger
authors.forename: C
authors.initials: C
authors.lastname: Theuser
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34; D002066:Busulfan / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016898:Interferon-alpha / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods*; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D018952:Antigens, CD34; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D003561:Cytarabine; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine